GSK's malaria vaccine to go to regulators in 2014
This article was originally published in Scrip
GlaxoSmithKline's pioneering malaria vaccine looks like it could arrive within two years. The company says it will file for approval of the RTS,S vaccine with the European Medicines Agency next year, based on the latest data from its large-scale Phase III trial. It added that the World Health Organization has indicated that a policy recommendation for the RTS,S malaria vaccine candidate is possible as early as 2015 if it is granted a positive scientific opinion by EMA, paving the way for decisions by African nations regarding large-scale implementation of the vaccine through their national immunization programs.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.